Objective: To investigate the occurrence and influencing factors of anemia in lymphoma patients and its effect on treatment. Methods: A total of 501 lymphoma patients, who were hospitalized in four general hospitals in Shanghai from January 2017 to June 2018, were followed up for six months. The clinical data about anemia were collected and statistically analyzed. Results: Among all the enrollment patients, there were 178 patients (35.5%) had anemia. Among 289 patients whom were initially treated for lymphoma, there were 99 patients (34.3%) with anemia. In the following-up time, there were 136 new cases (42.1%) of anemia. The total prevalence of anemia was 62.7%. The univariate analysis indicated that the anemia incidence for initially treated lymphoma patients was significantly related to their age, pathological type, bone marrow infiltration, IPI scores and Ann Arbor stage. The response to initially treatment in lymphoma patients with anemia was inferior to those without anemia. The multivariate analysis indicated that IPI scores 3-5 points (P<0.001, OR=4.230, 95%CI 2.339-7.650) and chemotherapy treatment (P<0.001, OR=11.049, 95%CI 5.149-23.711) were the independent influential factors to the emerging anemia incidence. PS score used to evaluate patient physical condition was obviously related to the anemia occurrence. Conclusion: Lymphoma patients have a high prevalence and incidence of anemia. The occurrence and severity of anemia are closely related to the efficacy and physical condition of lymphoma patients.
目的： 研究淋巴瘤患者贫血的发生情况、影响因素及其对疗效的影响。 方法： 对上海地区4所综合性医院2017年1月至2018年6月住院的501例淋巴瘤患者进行6个月随访，统计分析贫血相关临床资料。 结果： 501例淋巴瘤患者中178例（35.5%）伴有贫血；初治淋巴瘤289例，其中贫血患者99例（34.3%）；调查过程中新发贫血136例（42.1%）；整个调查过程，贫血患病率达62.7%。单因素分析结果显示：初治淋巴瘤患者贫血发生与年龄、病理类型、有无骨髓浸润、国际预后指数（IPI）评分及Ann Arbor分期相关；初治淋巴瘤伴有贫血的患者较无贫血患者疗效差。多因素分析结果显示：IPI评分3~5分（P<0.001，OR=4.230，95%CI 2.339~7.650）及化疗（P<0.001，OR=11.049，95%CI 5.149~23.711）是新发贫血的独立危险因素，患者的体能状态评分（PS评分）与贫血显著相关。 结论： 淋巴瘤患者贫血发病率及患病率高，贫血的发生与严重程度与淋巴瘤患者疗效及体能状态密切相关。.
Keywords: Anemia; Influence factors; Lymphoma.